Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-esca...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel, Christian, Burchert, Andreas, Hochhaus, Andreas, Saussele, Susanne, Neubauer, Andreas, Lauseker, Michael, Krause, Stefan W., Kolb, Hans-Jochem, Hossfeld, Dieter Kurt, Nerl, Christoph, Baerlocher, Gabriela M., Heim, Dominik, Brümmendorf, Tim H, Fabarius, Alice, Haferlach, Claudia, Schlegelberger, Brigitte, Balleisen, Leopold, Goebeler, Maria-Elisabeth, Hänel, Mathias, Ho, Anthony, Dengler, Jolanta, Falge, Christiane, Möhle, Robert, Kremers, Stephan, Kneba, Michael, Stegelmann, Frank, Köhne, Claus-Henning, Lindemann, Hans-Walter, Waller, Cornelius F., Spiekermann, Karsten, Berdel, Wolfgang E., Müller, Lothar, Edinger, Matthias, Mayer, Jiri, Beelen, Dietrich W., Bentz, Martin, Link, Hartmut, Hertenstein, Bernd, Fuchs, Roland, Wernli, Martin, Schlegel, Frank, Schlag, Rudolf, de Wit, Maike, Trümper, Lorenz, Hebart, Holger, Hahn, Markus, Thomalla, Jörg, Scheid, Christof, Schafhausen, Philippe, Verbeek, Walter, Eckart, Michael J., Gassmann, Winfried, Schenk, Michael, Brossart, Peter, Wündisch, Thomas, Geer, Thomas, Bildat, Stephan, Schäfer, Erhardt, Hasford, Joerg, Hehlmann, Rüdiger, Pfirrmann, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518910/
https://www.ncbi.nlm.nih.gov/pubmed/30514803
http://dx.doi.org/10.3324/haematol.2018.206797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518910/
https://www.ncbi.nlm.nih.gov/pubmed/30514803
http://dx.doi.org/10.3324/haematol.2018.206797

Ejemplares similares